Allergy Therapeutics (AGY) Share Price, News & Analysis

Company Overview

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group has achieved over 9% compound annual growth since formation and employs c.500 employees.

Key Stats

• Today's Range: 6.28 to 6.80
• 50-Day Range: 5.50 to 7.70
• 52-Week Range: 2.20 to 8
• Volume: 185,172 shs
• Average Volume: 440,302 shs
• Market Capitalization: £334.22 million
• P/E Ratio: N/A
• Dividend Yield: 8.33%
• Price Target: N/A
• Consensus Rating: N/A

AGY Stock Analysis - Frequently Asked Questions

How have AGY shares performed this year?

Allergy Therapeutics' stock was trading at GBX 6.53 on January 1st, 2025. Since then, AGY stock has increased by 4.2% and is now trading at GBX 6.80.
View the best growth stocks for 2025 here.

How were Allergy Therapeutics' earnings last quarter?

Allergy Therapeutics plc (LON:AGY) posted its quarterly earnings data on Wednesday, November, 6th. The company reported ($1.07) EPS for the quarter. Allergy Therapeutics had a negative net margin of 72.86% and a negative trailing twelve-month return on equity of 266.59%.

How do I buy shares of Allergy Therapeutics?

Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Allergy Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allergy Therapeutics investors own include (RLYP) (RLYP), Royalty Pharma (RPRX), genedrive (GDR), Intel (INTC), IQE (IQE), AstraZeneca (AZN) and Babcock International Group (BAB).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 2/22/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: LON:AGY
• CUSIP: N/A
• CIK: N/A
• Web: www.allergytherapeutics.com
• Phone: +44-1903-844700
• Fax: N/A
• Employees: 612
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (1.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: -30.7
• Net Income: £-52,591,209.13
• Net Margins: -72.86%
• Pretax Margin: N/A
• Return on Equity: -266.59%
• Return on Assets: -34.76%

Debt

• Debt-to-Equity Ratio: 835.48
• Current Ratio: 1.63
• Quick Ratio: 1.48

Sales & Book Value

• Annual Sales: £72.18 million
• Price / Sales: 4.63
• Cash Flow: GBX 1.86 per share
• Price / Cash Flow: 3.66
• Book Value: GBX 0.10 per share
• Price / Book: 68.91

Miscellaneous

• Outstanding Shares: 4,915,066,273
• Free Float: N/A
• Market Cap: £334.22 million
• Optionable: Not Optionable
• Beta: 1.40